A BILL 
To amend title XVIII of the Social Security Act to require 
the Secretary of Health and Human Services to negotiate 
prices of prescription drugs furnished under part D of 
the Medicare program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medicare Negotiation 
4
and Competitive Licensing Act of 2019’’. 
5
SEC. 2. REQUIRING THE SECRETARY OF HEALTH AND 
6
HUMAN SERVICES TO NEGOTIATE PRICES OF 
7
PRESCRIPTION DRUGS FURNISHED UNDER 
8
PART D OF THE MEDICARE PROGRAM. 
9
Section 1860D–11 of the Social Security Act (42 
10
U.S.C. 1395w–111) is amended by striking subsection (i) 
11
and inserting the following new subsection: 
12
‘‘(i) NEGOTIATION OF LOWER DRUG PRICES.— 
13
‘‘(1) IN GENERAL.—Notwithstanding any other 
14
provision of law, the Secretary shall, for plan years 
15
beginning on or after the date of the enactment of 
16
this subsection, negotiate with pharmaceutical man-
17
ufacturers the prices (including discounts, rebates, 
18
00:51 Feb 20, 2019
H1046
3 
•HR 1046 IH
and other price concessions) that may be charged to 
1
PDP sponsors and MA organizations during a nego-
2
tiated price period (as specified by the Secretary) for 
3
covered part D drugs for part D eligible individuals 
4
who are enrolled under a prescription drug plan or 
5
under an MA–PD plan. In negotiating such prices 
6
under this section, the Secretary shall take into ac-
7
count the following factors: 
8
‘‘(A) The comparative clinical effectiveness 
9
and cost effectiveness, when available from an 
10
impartial source, of such drug. 
11
‘‘(B) The budgetary impact of providing 
12
coverage of such drug. 
13
‘‘(C) The number of similarly effective 
14
drugs or alternative treatment regimens for 
15
each approved use of such drug. 
16
‘‘(D) The associated financial burden on 
17
patients that utilize such drug. 
18
‘‘(E) The associated unmet patient need 
19
for such drug. 
20
‘‘(F) The total revenues from global sales 
21
obtained by the manufacturer for such drug 
22
and the associated investment in research and 
23
development of such drug by the manufacturer. 
24
00:51 Feb 20, 2019
H1046
4 
•HR 1046 IH
‘‘(2) FINALIZATION OF NEGOTIATED PRICE.— 
1
The negotiated price of each covered part D drug for 
2
a negotiated price period shall be finalized not later 
3
than 30 days before a PDP sponsor is required to 
4
submit information described in subsection (b)(2) 
5
for the first plan year in such negotiated price pe-
6
riod. 
7
‘‘(3) COMPETITIVE LICENSING AUTHORITY.— 
8
‘‘(A) IN GENERAL.—Notwithstanding any 
9
exclusivity under clause (iii) or (iv) of section 
10
505(j)(5)(F) of the Federal Food, Drug, and 
11
Cosmetic Act, clause (iii) or (iv) of section 
12
505(c)(3)(E) of such Act, section 351(k)(7)(A) 
13
of the Public Health Service Act, or section 
14
527(a) of the Federal Food, Drug, and Cos-
15
metic Act, or by an extension of such exclusivity 
16
under section 505A of such Act or section 505E 
17
of such Act, and any other provision of law that 
18
provides for market exclusivity (or extension of 
19
market exclusivity) with respect to a drug, in 
20
the case that the Secretary is unable to success-
21
fully negotiate an appropriate price for a cov-
22
ered part D drug for a negotiated price period, 
23
the Secretary shall authorize the use of any 
24
patent, clinical trial data, or other exclusivity 
25
00:51 Feb 20, 2019
H1046
5 
•HR 1046 IH
granted by the Federal government with respect 
1
to such drug as the Secretary determines ap-
2
propriate for purposes of manufacturing such 
3
drug for sale under a prescription drug plan or 
4
MA–PD plan. Any entity making use of a com-
5
petitive license to use patent, clinical trial data, 
6
or other exclusivity under this section shall pro-
7
vide to the manufacturer holding such exclu-
8
sivity reasonable compensation, as determined 
9
by the Secretary based on the following factors: 
10
‘‘(i) The risk-adjusted value of any 
11
Federal government subsidies and invest-
12
ments in research and development used to 
13
support the development of such drug. 
14
‘‘(ii) The risk-adjusted value of any 
15
investment made by such manufacturer in 
16
the research and development of such 
17
drug. 
18
‘‘(iii) The impact of the price, includ-
19
ing license compensation payments, on 
20
meeting the medical need of all patients. 
21
‘‘(iv) The relationship between the 
22
price of such drug, including compensation 
23
payments, and the health benefits of such 
24
drug. 
25
00:51 Feb 20, 2019
H1046
6 
•HR 1046 IH
‘‘(v) Other relevant factors determined 
1
appropriate by the Secretary to provide 
2
reasonable compensation. 
3
‘‘(B) REASONABLE
COMPENSATION.—The 
4
manufacturer described in subparagraph (A) 
5
may seek recovery against the United States in 
6
the United States Court of Federal Claims. 
7
‘‘(C) INTERIM PERIOD.— 
8
‘‘(i) IN GENERAL.—Until 1 year after 
9
a drug described in subparagraph (A) is 
10
approved under section 505(j) of the Fed-
11
eral Food, Drug, and Cosmetic Act or sec-
12
tion 351(k) of the Public Health Service 
13
Act and is provided under license issued by 
14
the Secretary under such subparagraph, 
15
PDP plans and MA–PD plans shall not 
16
pay more for such drug than the average 
17
of the prices available, during the most re-
18
cent 12-month period for which data is 
19
available prior to the beginning of such ne-
20
gotiated price period, from the manufac-
21
turer to any wholesaler, retailer, provider, 
22
health maintenance organization, nonprofit 
23
entity, or governmental entity in the ten 
24
OECD (Organization for Economic Co-
25
00:51 Feb 20, 2019
H1046
7 
•HR 1046 IH
operation and Development) countries that 
1
have the largest gross domestic product 
2
with a per capita income that is not less 
3
than half the per capita income of the 
4
United States. 
5
‘‘(ii) FEDERAL
PROGRAM
LICENS-
6
ING.—If such drug is not made available 
7
at the price determined, the Secretary shall 
8
authorize such entities to use any patent, 
9
clinical trial data, or other exclusivity 
10
granted by the Federal government with 
11
respect to such drug as the Secretary de-
12
termines appropriate for purposes of man-
13
ufacturing such drug for sale under any 
14
Federal program, including those provided 
15
by Medicare, Medicaid, Veterans Affairs, 
16
the Department of Defense, and the Coast 
17
Guard. 
18
‘‘(D) AUTHORIZATION FOR SECRETARY TO 
19
PROCURE DRUGS DIRECTLY.— 
20
‘‘(i) IN
GENERAL.—The Secretary 
21
may procure a drug manufactured pursu-
22
ant to a competitive license under subpara-
23
graph (A) for purposes of this part or pur-
24
suant to a Federal program license under 
25
00:51 Feb 20, 2019
H1046
8 
•HR 1046 IH
subparagraph (C)(ii) for purposes of a 
1
Federal program directly from the entity 
2
manufacturing the drug pursuant to such 
3
a license. 
4
‘‘(ii) CLARIFICATION REGARDING AP-
5
PLICATION
OF
BUY
AMERICAN
ACT.—In 
6
the case where the Secretary procures a 
7
drug under this subparagraph, the provi-
8
sions of chapter 83 of title 41, United 
9
States Code (commonly referred to as the 
10
‘Buy American Act’) shall apply. 
11
‘‘(E) PRIORITY FOR U.S. MANUFACTURERS 
12
IN AUTHORIZING COMPETITIVE LICENSES.—In 
13
authorizing a competitive license under this 
14
paragraph, the Secretary— 
15
‘‘(i) shall give preference to entities 
16
that the Secretary determines have the 
17
highest safety and security standards; and 
18
‘‘(ii) may give priority to entities that 
19
will manufacture such drug in the United 
20
States. 
21
‘‘(4) FDA REVIEW OF LICENSED DRUG APPLI-
22
CATIONS.—The Secretary shall prioritize review of 
23
applications under section 505(j) of the Federal 
24
00:51 Feb 20, 2019
H1046
9 
•HR 1046 IH
Food, Drug, and Cosmetic Act for drugs licensed 
1
under paragraph (3)(A). 
2
‘‘(5) PROHIBITION
OF
ANTICOMPETITIVE
BE-
3
HAVIOR.—No drug manufacturer may engage in 
4
anticompetitive behavior with another manufacturer 
5
that may interfere with the issuance and implemen-
6
tation of a competitive license or run contrary to 
7
public policy. 
8
‘‘(6) REQUIRED
REPORTING.—The Secretary 
9
may require pharmaceutical manufacturers to dis-
10
close to the Secretary such information that the Sec-
11
retary determines necessary for purposes of carrying 
12
out this subsection. 
13
‘‘(7) CLARIFICATION.—Nothing in this sub-
14
section shall be construed as preventing the sponsor 
15
of a prescription drug plan or an organization offer-
16
ing an MA–PD plan from obtaining a discount or 
17
reduction of the price for a covered part D drug 
18
below the price negotiated by the Secretary.’’. 
19
Æ 
00:51 Feb 20, 2019
H1046
